CoxaPro
> Clinical Library > Tervetuloa Clinical Libraryyn > Short-Term Follow-Up of Patellar Component Revision in Patients With Isolated Patellar Component Loosening
The Journal of Arthroplasty, Volume 35, Issue 8, 2177 - 2181
Knee
Link to article
Short-Term Follow-Up of Patellar Component Revision in Patients With Isolated Patellar Component Loosening
Brustein, Jason A. et al.Knee
Background
The etiology of patellar component loosening can be multifactorial, including component malposition, trauma, infection, and poor implant design. These cases may be managed with isolated patellar component revision or simultaneous patellar component with femoral and/or tibial component revision. Isolated patellar revision in the setting of aseptic loosening historically has had limited success with high rates of repeat revision.
Methods
We performed a retrospective cohort study of 75 cases diagnosed with patellar component loosening that underwent revision. Patients were followed for a minimum of 2 years. Cases were categorized as either isolated patellar (IP) revision or patellar with femoral and/or tibial component (P + O) revisions. Survivorship and re-revision causes were compared between groups. Secondary outcomes included surgical time, estimated blood loss, range of motion, and length of stay.
Results
Fifty patients underwent IP revision, and 25 patients had P + O revision. Overall survivorship at the 2-year follow-up interval was 94.6%. Survivorship of IP revision undertaken for aseptic loosening was 94%. Survivorship of P + O revision was 96%. Eight percent of patients required reoperation from the P + O revision group, while 12% of patients in the IP revision group underwent a reoperation. Patients undergoing IP revision had better postoperative range of motion, lower surgical times, lower estimated blood loss, and decreased length of stay.
Conclusion
IP revision demonstrates excellent survivorship and clinical outcomes comparable to P + O revision. When appropriate, IP revision should be considered as a potential treatment option.
Level of Evidence
Level III, retrospective cohort study.
Link to article